A trial looking at datopotamab deruxtecan and durvalumab for breast cancer (TROPION-Breast04)

This trial is comparing datopotamab deruxtecan and durvalumab with pembrolizumab and standard chemotherapy before surgery for breast cancer. It is also comparing some of these treatments after surgery for breast cancer.

You pronounce datopotamab deruxtecan as day-toe-pot-oh-mab deh-rux-tee-can. It is also called Dato-DXd for short.

The trial is for people who haven’t had treatment yet and have:

• triple negative breast cancer or

• breast cancer that has low levels of receptors for the hormones oestrogen and progesterone and no receptors for HER2. Your doctor will know this.